TGFβ signaling: its role in fibrosis formation and myopathies
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Modifiers of TGFβ signaling have been investigated as treatment options for several types of muscle diseases. The purpose of this review is to focus on the most recent studies that have used this treatment strategy for pathological muscle disorders. We also review the recent insight into the mechanistic processes by which TGFβ signaling contributes to these pathologies by promoting fibrosis formation. RECENT FINDINGS: Recent research has shed light on the role of TGFβ signaling in the regulation of microRNAs associated with fibrosis formation. Inhibition of TGFβ signaling by Losartan treatment greatly improved the phenotype of myopathies associated with laminin-α2-deficient congenital muscular dystrophy. Caveolin 3 deficiency was also ameliorated by the use of several different types of TGFβ signaling inhibitors. Use of Losartan had dramatically beneficial effects on sarcopenic muscle by improving the regeneration after injury. Pharmacological manipulation to increase muscle mass is an emerging trend in obesity treatment research. New advances in the use of potent myostatin inhibitors have made this an attractive approach for future studies. SUMMARY: An increasing number of skeletal myopathies are demonstrating favorable responses to alterations of the TGFβ signaling pathway. However, future research is needed to fully understand the downstream molecular signature associated with this pathway in order to develop more specific targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., et al. (2006) · Science · doi:10.1126/science.1124287 · Cited by 1,794
Self-citationAberrant repair and fibrosis development in skeletal muscle
Mann, C. J., Perdiguero, E., Kharraz, Y., Aguilar, S., Pessina, P., Serrano, A. L., & Muñoz-Cánoves, P. (2011) · Skeletal Muscle · doi:10.1186/2044-5040-1-21 · Cited by 853 · cited 3×
“A surplus of extracellular matrix (ECM) protein produced by the muscle fibroblasts, called myofibroblasts, during the initial stages of muscle fiber necrosis also inhibits the normal regeneration process [9,19].”
Protection from obesity and diabetes by blockade of TGF-β/smad3 signaling
Yadav, H., Quijano, C., Kamaraju, A. K., Gavrilova, O., Malek, R., Chen, W., Zerfas, P., Zhigang, D., Wright, E. C., Stuelten, C., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.04.013 · Cited by 709
Suppression of body fat accumulation in myostatin-deficient mice
McPherron, A. C., & Lee, S.-J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0213562 · Cited by 505 · cited 1×
“When myostatin knockout mice are crossed to genetic models of obesity, such as the leptin-deficient model, they are protected from obesity [45].”
Regulation of muscle growth by multiple ligands signaling through activin type II receptors
Lee, S.-J., Reed, L. A., Davies, M. V., Girgenrath, S., Goad, M. E. P., Tomkinson, K. N., Wright, J. F., Barker, C., Ehrmantraut, G., Holmstrom, J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505996102 · Cited by 501
Regulation and dysregulation of fibrosis in skeletal muscle
Serrano, A. L., & Muñoz-Cánoves, P. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.05.035 · Cited by 290
Cellular and Molecular Mechanisms Regulating Fibrosis in Skeletal Muscle Repair and Disease
Serrano, A. L., Mann, C. J., Vidal, B., Ardite, E., Perdiguero, E., & Muñoz-Cánoves, P. (2011) · Current Topics in Developmental Biology · doi:10.1016/b978-0-12-385940-2.00007-3 · Cited by 200
Histone deacetylase 4 is required for TGFβ1-induced myofibroblastic differentiation
Glenisson, W., Castronovo, V., & Waltregny, D. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.05.016 · Cited by 153 · cited 1×
“It has previously been reported that HDAC4 is required for TGFb-induced differentiation to myofibroblasts [25].”
Cited by
Csapo, R., Gumpenberger, M., & Wessner, B. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00253 · Cited by 429
Mechanisms for fiber-type specificity of skeletal muscle atrophy
Wang, Y., & Pessin, J. E. (2013) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e328360272d · Cited by 414
The arterial microenvironment: the where and why of atherosclerosis
Yurdagul, A., Finney, A. C., Woolard, M. D., & Orr, A. W. (2016) · Biochemical Journal · doi:10.1042/bj20150844 · Cited by 185
Skeletal muscle fibrosis in pancreatic Cancer patients with respect to survival
Judge, S. M., Nosacka, R. L., Delitto, D., Gerber, M. H., Cameron, M. E., Trevino, J. G., & Judge, A. R. (2018) · JNCI Cancer Spectrum · doi:10.1093/jncics/pky043 · Cited by 91
Regulation of transport across cell membranes by the serum- and glucocorticoid-inducible kinase SGK1
Lang, F., Stournaras, C., & Alesutan, I. (2014) · Molecular Membrane Biology · doi:10.3109/09687688.2013.874598 · Cited by 66
Metadata
- Authors
- MacDonald, E. M., & Cohn, R. D.
- Venue
- Current Opinion in Rheumatology
- Published
- 2012-11
- Volume
- 24
- Issue
- 6
- Pages
- 628-634
- ISSN
- 1040-8711 (ISSN-L)
- OpenAlex
- W2063455378
- Cited by
- 84
- References
- 8
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.